National and Kapodistrian University of Athens
Χημειοευαισθησία in vitro και μοριακή ανάλυση του καρκίνου του μαστού: συσχετισμός με την κλινική πράξη
Abstract
dc:descriptionAim To correlate in vitro chemosensitivity and chemoresistance with clinical outcome in patients with breast cancer. Also to correlate the expression of MDR1, nm23-H1 and SEMA 3C (previous named as H Sema E) genes with response to treatment and survival in breast cancer patients. Methods Patients with breast cancer who were going to have a procedure for diagnostic or therapeutic purposes, were eligible for the study, providing a sample of the tumor could be send to our laboratory for the tests. The assay used for the in vitro chemosensitivity studies, was a modified clonogenic method. The molecular analysis studies were done with the Reverse Transcriptase- Polymerase Chain Reaction (RT-PCR) method. Results were compared with the clinical response to treatment and the overall survival. WHO’s criteria were used for assessing clinical response to the treatment. The statistical analysis was performed with logistic regression. Results During a three years time, 36 patients of median age 55 were included in the study. Most of them (70%) had metastatic disease. The assessability rate of the method was 53%, although in fluid specimens, the accessibility rate reached 72% which can be compared to larger than this study. The negative predictive value of the assay was 100% but the positive one only 17%. Expression of MDR1 was detected in 83% of the patients. The percentage of patients responding to the chemotherapy was about the same both in MDR1 positive and MDR1 negative patients. There was a trend of longer survival in women negative for the gene. Regarding nm23-H1 gene, longer median survival was observed in patients who didn’t express the gene. More specifically, nm23-H1 negative patients with metastatic disease, had a median survival of 49 months, compared to a median survival of 6 months in positive for the gene patients. Similarly there was a trend of longer median survival in SEMA 3C (previously named H Sema E) negative patients. Of notice was the finding of resistance to the chemotherapy in two patients negative for the MDR1 but positive for the SEMA 3C (previously named H Sema E), while a third patient both MDR1 and SEMA 3C (previously named H Sema E) negative, responded to the chemotherapy Conclusions It seems that the in vitro chemosensitivity and chemoresistance assay used, can help the clinician decide which drugs are ineffective for his patients, thus sparing them from the side-effects of ineffective drugs. It also seems that MDR1, nm23-H1 and SEMA 3C (previously named H Sema E) as detected by RT-PCR , could be used as prognostic markers in breast cancer patients. Larger prospective studies are needed for clarification of the above results.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2009
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Sgouros, Iosif
- Σγουρός, Ιωσήφ
Subjects
dc:subject × 15- Καρκίνος μαστού
- Χημειοευαισθησία in vitro
- Αντίστροφη μεταγραφάση της αλυσιδωτής αντίδρασης πολυμεράσης
- Εξατομικευμένη χημειοθεραπεία
- Breast cancer
- In vitro chemosensitivity and chemoresistance assays
- RT-PCR
- MDR1
- nn23-H1
- SEMA 3C
- Individualized chemotherapy
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/23772